Horizon Therapeutics plc (Nasdaq: HZNP) reported on Wednesday that executive vice president, chief financial officer Paul Hoelscher will retire on 16 May 2022, but will continue as an advisor to the company through to May 2023.
The company has named Aaron Cox, who was named executive vice president, finance, as successor to Hoelscher.
Having joined Horizon in 2016, Cox has served in various roles across business development and corporate development.
Most recently he served as senior vice president, corporate development and chief of staff to Tim Walbert, chairman, president and chief executive officer, Horizon.
Previously, Cox was vice president, capital markets at BMO Capital Markets and held investment banking roles at JMP Securities and Stout.
Horizon focuses on the discovery, development and commercialisation of medicines for people suffering from rare, autoimmune and severe inflammatory diseases.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca